Search research articles
Contact Us
Filters
Showing results (21-30 of 227) with videos related to
Page
of 23
Sort By:
Acta Oncologica (Stockholm, Sweden)
|
September 15, 2012
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects
Everardo D Saad, Marc Buyse
Journal of the National Cancer Institute
|
February 24, 2025
Noninferiority trials in oncology: need for improvement, or a paradigm shift?
Marc Buyse, Everardo D Saad
Cancers
|
November 24, 2020
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Everardo Delforge Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer
Angelo Di Leo, Marc Buyse
Clinical Investigation
|
March 3, 2015
Data fraud in clinical trials
Stephen L George, Marc Buyse
Clinical Trials (London, England)
|
July 16, 2020
Commentary on Bamat et al
Everardo D Saad, Marc Buyse
Expert Review of Anticancer Therapy
|
March 22, 2003
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer
Laurent Zelek, Pascal Piedbois, Marc Buyse
The Lancet. Oncology
|
June 15, 2016
Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
Arlene Chan, Marc Buyse, Bin Yao
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Laurence Collette, Marc Buyse, Tomasz Burzykowski
Drugs
|
June 3, 2017
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors"
Stefan Michiels, Everardo D Saad, Marc Buyse
Page
of 23
Search research articles
Search
Showing results (21-30 of 227) with videos related to
Sort By:
Page
of 23
Acta Oncologica (Stockholm, Sweden)
|
September 15, 2012
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects
Everardo D Saad, Marc Buyse
Journal of the National Cancer Institute
|
February 24, 2025
Noninferiority trials in oncology: need for improvement, or a paradigm shift?
Marc Buyse, Everardo D Saad
Cancers
|
November 24, 2020
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Everardo Delforge Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer
Angelo Di Leo, Marc Buyse
Clinical Investigation
|
March 3, 2015
Data fraud in clinical trials
Stephen L George, Marc Buyse
Clinical Trials (London, England)
|
July 16, 2020
Commentary on Bamat et al
Everardo D Saad, Marc Buyse
Expert Review of Anticancer Therapy
|
March 22, 2003
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer
Laurent Zelek, Pascal Piedbois, Marc Buyse
The Lancet. Oncology
|
June 15, 2016
Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
Arlene Chan, Marc Buyse, Bin Yao
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Laurence Collette, Marc Buyse, Tomasz Burzykowski
Drugs
|
June 3, 2017
Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors"
Stefan Michiels, Everardo D Saad, Marc Buyse
Page
of 23